Among the 58 cases of lung cancer with SMARCA4 LOF mutations in our study, the mutation rates corresponding to the above hot genes were almost consistent with the previously reported rates of 74.1%, 31.0%, 24.1%, 20.7%, and 15.5% for TP53, KEAP1, STK11, KRAS, and EGFR, respectively. This evidence concerns the gene KRAS and lung carcinoma.